Breaking News Instant updates and real-time market news.

ABBV

AbbVie

$98.79

0.6 (0.61%)

, LYB

LyondellBasell

$113.07

1.155 (1.03%)

12:25
08/18/18
08/18
12:25
08/18/18
12:25

StAbbVie, Starbucks among dividend standouts, Barron's says

AbbVie (ABBV), LyondellBasell (LYB), Broadcom (AVGO), Regions Financial (RF) and Starbucks (SBUX) sport high yields and good dividend growth, a combination that is not that common, Lawrence Strauss writes in this week's edition of Barron's. Reference Link

ABBV

AbbVie

$98.79

0.6 (0.61%)

LYB

LyondellBasell

$113.07

1.155 (1.03%)

AVGO

Broadcom

$209.27

0.6 (0.29%)

RF

Regions Financial

$19.48

0.09 (0.46%)

SBUX

Starbucks

$53.58

0.53 (1.00%)

  • 05

    Sep

  • 05

    Sep

  • 06

    Sep

  • 11

    Sep

  • 12

    Sep

  • 12

    Sep

ABBV AbbVie
$98.79

0.6 (0.61%)

07/27/18
PIPR
07/27/18
NO CHANGE
Target $100
PIPR
Neutral
Worries about AbbVie's Humira keep Piper Jaffray on sidelines
Piper Jaffray analyst Christopher Raymond said he finds "little to quibble with" in AbbVie's Q2 report, but also noted that while its FY18 EPS guidance was raised, its revenue guidance actually came down slightly. Raymond, who continues to worry that consensus does not fully factor in the extent of ex-U.S. Humira pressure or the further pressure from co-pay accumulator programs in the U.S., prefers to stay on the sidelines and keeps a Neutral rating on the shares. He also lowered his price target on AbbVie to $100 from $105.
06/22/18
FBCO
06/22/18
NO CHANGE
Target $89
FBCO
Underperform
AbbVie most exposed to biosimilar risk, says Credit Suisse
Credit Suisse analyst Vamil Divan reiterated an Underperform rating on AbbVie after the FDA further ramped up its focus on biosimilars. In a research note to investors, Divan said he was "intrigued" by the FDA's decision to withdraw its September 2017 Draft Guidance focused on evaluating analytical similarity with biosimilars, and believes the agency will release "more reasonable" guidance in the coming months that will expedite the approval and uptake of biosimilars. AbbVie is most exposed to Biosimilar risk, Divan says, with Humira accounting for about 60% of its total net present value, and is cautious on AbbVie's outlook in front of biosimilar competition in the EU later this year and in the U.S. by 2023.
08/08/18
HCWC
08/08/18
NO CHANGE
Target $44
HCWC
Buy
ObsEva price target raised to $44 from $30 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised his price target for ObsEva (OBSV) to $44 based on the disclosed pricing for AbbVie's (ABBV) Orilissa, the fgonadotropin-releasing hormone receptor antagonist for endometriosis and uterine fibroids. ObsEva management had previously guided to the cost of GnRH receptor antagonist therapy at $15 per day, about $450 per month, and the proposed monthly cost of Orilissa at $845 "appears to be comfortably above this level," Selvaraju tells investors in a research note. As such, the analyst elected to revise his pricing assumptions upward for ObsEva's linzagolix to reflect a daily cost of $25. He keeps a Buy rating on ObsEva shares.
07/24/18
SBSH
07/24/18
NO CHANGE
SBSH
Buy
Citi says Myovant may have $102 upside if relugolix priced at parity to elagolix
After AbbVie (ABBV) and Neurocrine Biosciences (NBIX) announced that the FDA approved elagolix and Neurocrine said the list price has been set at $28 per day, Citi analyst Robyn Karnauskas noted that she currently models Myovant Sciences' (MYOV) relugolix priced at $10 per day. Modeling relugolix pricing at parity to elagolix and assuming a gross-to-net of 100% would lead to a fair value estimate for Myovant of $146, or the equivalent of $102 of upside from her current price target of $44, Karnauskas stated. The analyst, who models a split market between relugolix and elagolix in endometriosis, keeps a Buy rating on Myovant shares.
LYB LyondellBasell
$113.07

1.155 (1.03%)

07/10/18
SBSH
07/10/18
INITIATION
Target $122
SBSH
Buy
LyondellBasell resumed with a Buy at Citi
Citi analyst P.J. Juvekar resumed coverage of LyondellBasell with a Buy rating and $122 price target. The rating is unchanged and the price target lowered from $125 relative to Citi's prior coverage. Fears of new capacity are already factored in and while trade war is a risk, most polyethylene grades sold by LyondellBasell have not been targeted by Chinese tariffs yet, Juvekar tells investors in a research note. The analyst believes integrated polyethylene margins should recover in 2019 as global supply/demand balances improve.
05/16/18
JEFF
05/16/18
UPGRADE
Target $137
JEFF
Buy
LyondellBasell upgraded to Buy from Hold at Jefferies
Jefferies analyst Laurence Alexander upgraded LyondellBasell to Buy and raised his price target for the shares to $137 from $118. The potential for higher oil prices in the second half of 2018 and 2019, favorable demand trends and a "strong" balance sheet do not appear to be fully reflected at current valuation levels, Alexander tells investors in a research note.
06/06/18
WELS
06/06/18
NO CHANGE
Target $130
WELS
Outperform
LyondellBasell price target raised to $130 from $125 at Wells Fargo
Wells Fargo analyst Frank Mitsch raised his price target for LyondellBasell to $130 from $125 on reduced sulfur regulations, taking effect on January 1, 2020, and as he expects to see more material moves in the heavy light spread sooner rather than later. The analyst reiterates an Outperform rating on the shares.
05/21/18
STPT
05/21/18
DOWNGRADE
STPT
Hold
LyondellBasell downgraded to Hold from Buy at Standpoint Research
AVGO Broadcom
$209.27

0.6 (0.29%)

08/07/18
LEHM
08/07/18
INITIATION
Target $265
LEHM
Overweight
Broadcom reinstated with an Overweight at Barclays
Barclays analyst Blayne Curtis reinstated coverage of Broadcom with an Overweight rating and $265 price target.
08/07/18
08/07/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Broadcom (AVGO) reinstated with an Overweight at Barclays. 2. ObsEva (OBSV) initiated with an Outperform at Wedbush. 3. Deciphera (DCPH) initiated with a Buy at Canaccord. 4. Alliance Data (ADS) assumed with a Buy at Jefferies. 5. Hermes (HESAY) initiated with an Equal Weight at Morgan Stanley. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/06/18
MSCO
08/06/18
NO CHANGE
MSCO
Boeing, Tesla, Nvidia make Morgan Stanley 'key man risk' list
Morgan Stanley equity strategist Mark Savino noted that about 12% of CEO jobs among S&P 500 companies turned over in 2017, noting that this was the highest level of CEO departures since before the financial crisis. The 59 stocks of S&P 500 companies that had CEOs depart in 2017 underperformed the market by 11% over the next 12 months, or since the departure for instances that were less than 12 months ago, noted Savino. In cooperation with the firm's U.S. analysts, Savino and his team identified the companies in each sector they believe face the greatest level of "key man risk," which includes: Boeing (BA), Tesla (TSLA), ADT Inc. (ADT), Moody's (MCO), TransUnion (TRU), Arista Networks (ANET), Church & Dwight (CHD), Coca-Cola (KO), Monster Beverage (MNST), Coupa Software (COUP), Salesforce (CRM), FireEye (FEYE), MongoDB (MDB), Microsoft (MSFT), New Relic (NEWR), XPO Logistics (XPO), Hilton (HLT), Las Vegas Sands (LVS), Best Buy (BBY), Ulta (ULTA), Aflac (AFL), Athene Holding (ATH), Lincoln National (LNC), Arthur J. Gallagher (AJG), Chubb (CB), Amazon.com (AMZN), Activision Blizzard (ATVI), Facebook (FB), Alphabet (GOOGL), Apple (AAPL), Terex (TEX), Cleveland-Cliffs (CLF), Freeport McMoRan (FCX), FleetCor (FLT), Global Payments (GPN), Square (SQ), Jazz Pharmaceuticals (JAZZ), Cheesecake Factory (CAKE), Broadcom (AVGO), Nvidia (NVDA), Chegg (CHGG), DXC Technology (DXC), Medidata (MDSO), Pluralsight (PS), RealPage (RP), Shopify (SHOP) and T-Mobile (TMUS).
08/09/18
MSCO
08/09/18
NO CHANGE
MSCO
Morgan Stanley downgrades semiconductor industry view to Cautious
Morgan Stanley analyst Joseph Moore said he has become less constructive on semiconductor stocks through the year and he now believes elevated inventory levels and stretched lead times leave "no margin for error." Given his view that any lead time adjustment or demand slowdown could drive a "meaningful correction," Moore has downgraded his semiconductor industry view to Cautious from In-Line. He favors connector companies, like Amphenol (APH) and TE Connectivity (TEL) over analog/MCU at this point in the cycle, due to lower risk around lead time issues, Moore said. He also has a "strong preference" for high margin and more defensive models, such as Analog Devices (ADI) over lower margin and commodity exposed ones, like Cypress Semiconductor (CY) and ON Semiconductor (ON), he said. Despite his more cautious view on the space, Moore keeps Overweight ratings on Nvidia (NVDA), Xilinx (XLNX) and Ambarella (AMBA), citing his view that they should benefit from secular growth in the area of AI, data center, and autonomous. Other semiconductor names include Microchip (MCHP), Qorvo (QRVO), Micron (MU), Intel (INTC), Broadcom (AVGO) and Qualcomm (QCOM).
RF Regions Financial
$19.48

0.09 (0.46%)

06/29/18
06/29/18
NO CHANGE

Goldman says Wells Fargo, Huntington, Regions among biggest winners of CCAR
Goldman Sachs analyst Richard Ramsden said the Fed's CCAR results came in largely better than expected, calling Wells Fargo (WFC), Huntington Bancshares (HBAN), Regions Financial (RF), SunTrust (STI) and Fifth Third (FITB) the biggest relative winners in his view. He believes the market will be focused on banks' 25% dividend growth announcements and believes the CCAR results can be a catalyst for a relief rally.
06/28/18
BARD
06/28/18
UPGRADE
Target $17
BARD
Neutral
Regions Financial upgraded to Neutral after pullback at Baird
As previously reported, Baird analyst David George upgraded Regions Financial to Neutral from Underperform. The analyst cited the recent pullback, which he thinks has made the valuation more reasonable. He believes the capital return is set to meaningfully increase and the company should remain the leader in total payout. George has a $17 price target on Regions Financial shares.
06/28/18
06/28/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Air Transport Services (ATSG) upgraded to Buy from Hold at Stifel with analyst David Ross saying shares are attractive at current levels given long-term growth prospects. 2. T-Mobile (TMUS) upgraded to Outperform from Market Perform at Wells Fargo with analyst Jennifer Fritzsche stating that recent conversations with some of his DC contacts have made him more optimistic that a deal to merge with Sprint (S) could be approved. 3. Talend (TLND) upgraded to Buy from Neutral at with analyst Tyler Radke saying a survey of Chief Data Officers shows "strong spending signals" while the company's competitive backdrop is favorable amid "increasing cloud tailwinds". 4. Regions Financial (RF) upgraded to Neutral from Underperform at Baird with analyst David George citing the recent pullback, which he thinks has made the valuation more reasonable. 5. Twilio (TWLO) upgraded to Buy from Hold at Argus with analyst Jim Kelleher saying the pullback in the stock price has created a more favorable entry point. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/29/18
WEDB
06/29/18
NO CHANGE
WEDB
Outperform
CCAR results 'very positive' for regional banks, says Wedbush
Wedbush analyst Peter Winter says the results of the CCAR for 2018 were "very positive" for the regional banks, as the average total capital return increased from 88% in the 2017 CCAR to 119%, above his forecast of 103%. In a research note to investors, Winter says the "winners" relative to his forecast were Regions Financial (RF), Huntington Bancshares (HBAN), Fifth Third (FITB), SunTrust (STI) and KeyCorp (KEY).
SBUX Starbucks
$53.58

0.53 (1.00%)

07/27/18
JPMS
07/27/18
NO CHANGE
Target $58
JPMS
Overweight
Starbucks trends 'aren't all that bad,' says JPMorgan
JPMorgan analyst John Ivankoe says the trends at Starbucks "aren't all that bad" and that it "probably feels worse than it is." The stock's current multiple is "low enough to remain patient," Ivankoe tells investors in a post-earnings research note. The company's U.S. comps may actually be running at 3% in Q4, with pricing, additional food sales and non-blended beverage comps up to offset weak blended beverage sales in the afternoon, the analyst adds. He lowered his price target for the shares to $58 from $61 and keeps an Overweight rating on Starbucks.
07/27/18
OPCO
07/27/18
NO CHANGE
Target $61
OPCO
Outperform
Starbucks price target lowered to $61 from $66 at Oppenheimer at Oppenheimer
Oppenheimer analyst Brian Bittner lowered his price target on Starbucks to $61 from $66 and maintained an Outperform rating following the company's quarterly results. In a research note to investors, Bittner says he believes the stock now presents an attractive opportunity and is ready to become more aggressive. With a tough FY18 "almost in the rear-view" and stock valued at 19x earnings, he believes SSS of 3%+ from here represents a catalyst.
07/27/18
PIPR
07/27/18
NO CHANGE
Target $60
PIPR
Overweight
Piper reiterates Overweight rating on Starbucks after Q3 results
Piper Jaffray analyst Nicole Miller Regan views Starbucks' fiscal Q3 results as generally in-line with the pre-release. The results underscore the "sheer variety of issues management is working to address," Regan tells investors in a post-earnings research note. The analyst, however, continues to see "substantial value" in the opportunity for long-term store growth in China, ongoing leverage of the recently announced Nestle alliance, and the ongoing premiumization of the brand on a global scale through the growth of the roastery and reserve bar locations. She reiterates an Overweight rating on Starbucks with a $60 price target.
07/24/18
BMOC
07/24/18
NO CHANGE
Target $51
BMOC
Market Perform
Starbucks price target lowered to $51 from $56 at BMO Capital
BMO Capital analyst Andrew Strelzik lowered his price target on Starbucks to $51 and kept his Market Perform rating, citing the findings of his cannibalization analysis from data over the past 12 months. The analyst says the results suggest "continued risk" to the company's growth targets, with U.S. comps headwinds and a potentially deeper slowdown in the domestic store count growth. Strelzik adds that Starbucks' "overlap metrics are near or above the previous highs", while the company's focus on opening stores in the under-penetrated markets "isn't moving the needle".

TODAY'S FREE FLY STORIES

CDTI

CDTi

$0.34

0.01 (3.08%)

18:15
09/21/18
09/21
18:15
09/21/18
18:15
Hot Stocks
CDTi sees September 21 as effective date of reverse stock split »

CDTi Advanced Materials…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DUK

Duke Energy

$79.82

-0.81 (-1.00%)

18:08
09/21/18
09/21
18:08
09/21/18
18:08
Hot Stocks
Duke Energy restored nearly 1.8M outages in NC, SC during past week »

Duke Energy crews today…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 02

    Oct

  • 03

    Oct

  • 04

    Oct

  • 11

    Nov

JNJ

Johnson & Johnson

$142.85

0.85 (0.60%)

18:01
09/21/18
09/21
18:01
09/21/18
18:01
Hot Stocks
Johnson & Johnson's Janssen discloses phase 3 study results of Esketamine »

The Janssen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 28

    Oct

UAL

United Continental

$89.94

0.8 (0.90%)

17:39
09/21/18
09/21
17:39
09/21/18
17:39
Periodicals
United pilots refuse contract changes on regional routes, Reuters says »

United Airlines pilots…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

XLE

Energy Select Sector SPDR

$75.11

0.5132 (0.69%)

, XLU

Utilities SPDR

$53.04

0.2049 (0.39%)

17:36
09/21/18
09/21
17:36
09/21/18
17:36
General news
Week ending ETF Scorecard: Materials outperform, Utlilites slump »

S&P500 SECTORS:…

XLE

Energy Select Sector SPDR

$75.11

0.5132 (0.69%)

XLU

Utilities SPDR

$53.04

0.2049 (0.39%)

IYR

DJ US Real Estate Index Fund

$81.88

-0.06 (-0.07%)

XLP

Consumer Staples Sector SPDR

$55.02

0.1285 (0.23%)

XLY

Consumer Discretionary Sector SPDR

$116.98

-0.4288 (-0.37%)

XLB

S&P Select Materials SPDR

$60.54

-0.1312 (-0.22%)

XLF

Financial Select Sector

$28.73

-0.1175 (-0.41%)

XLV

Health Care Select Sector SPDR

$94.26

0.1571 (0.17%)

XLK

Technology Select Sector SPDR

$74.68

-0.2056 (-0.27%)

XLI

Industrial Select Sector SPDR

$79.71

0.2338 (0.29%)

GLD

SPDR Gold Trust

$113.48

-0.77 (-0.67%)

SLV

iShares Silver Trust

$13.44

-0.01 (-0.07%)

USO

United States Oil Fund

$14.95

0.145 (0.98%)

UNG

United States Natural Gas Fund

$24.60

0.235 (0.96%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$86.24

0.05 (0.06%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$114.72

0.04 (0.03%)

TLT

iShares 20+ Year Treasury Bond Fund

$117.12

-0.02 (-0.02%)

IEF

iShares 7-10 Year Treasury Bond ETF

$101.00

0.03 (0.03%)

SHY

iShares 1-3 Year Treasury Bond

$83.05

0.02 (0.02%)

IWD

iShares Russell 1000 Value

$129.51

0.13 (0.10%)

IWF

iShares Russell 1000 Growth

$155.30

-0.55 (-0.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OHGI

One Horizon Group

$0.18

-0.0088 (-4.63%)

17:34
09/21/18
09/21
17:34
09/21/18
17:34
Syndicate
Breaking Syndicate news story on One Horizon Group »

One Horizon Group files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CYTX

Cytori Therapeutics

$0.41

-0.033 (-7.38%)

17:31
09/21/18
09/21
17:31
09/21/18
17:31
Syndicate
Breaking Syndicate news story on Cytori Therapeutics »

Cytori Therapeutics files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NEM

Newmont Mining

$31.56

0.05 (0.16%)

17:22
09/21/18
09/21
17:22
09/21/18
17:22
Syndicate
Breaking Syndicate news story on Newmont Mining »

Newmont Mining files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 25

    Oct

CB

Chubb

$139.87

-0.05 (-0.04%)

17:22
09/21/18
09/21
17:22
09/21/18
17:22
Hot Stocks
Chubb CEO Greenberg sells $8.6M in common stock »

Chubb CEO Evan Greenberg…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VTVT

vTv Therapeutics

$0.80

0.0096 (1.21%)

17:21
09/21/18
09/21
17:21
09/21/18
17:21
Hot Stocks
vTv says FDA advised that azeliragon efficacy be shown in at least 2 trials »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VYGR

Voyager Therapeutics

$18.21

-0.27 (-1.46%)

17:17
09/21/18
09/21
17:17
09/21/18
17:17
Hot Stocks
Breaking Hot Stocks news story on Voyager Therapeutics »

Armistice Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNRC

Generac

$57.99

-0.02 (-0.03%)

17:16
09/21/18
09/21
17:16
09/21/18
17:16
Hot Stocks
Generac announces new $250M share repurchase program »

The company announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GBNK

Guaranty Bancorp

$30.20

-0.5 (-1.63%)

, IBTX

Independent Bank

$67.60

-1.15 (-1.67%)

17:13
09/21/18
09/21
17:13
09/21/18
17:13
Conference/Events
Independent Bank to host special shareholder meeting »

Special Shareholder…

GBNK

Guaranty Bancorp

$30.20

-0.5 (-1.63%)

IBTX

Independent Bank

$67.60

-1.15 (-1.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 25

    Sep

HRS

Harris

$164.33

1.685 (1.04%)

17:13
09/21/18
09/21
17:13
09/21/18
17:13
Hot Stocks
Harris awarded $255.4M Department of Defense contract »

Harris Corp has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PMBC

Pacific Mercantile Bancorp

$9.25

-0.5 (-5.13%)

17:10
09/21/18
09/21
17:10
09/21/18
17:10
Hot Stocks
Breaking Hot Stocks news story on Pacific Mercantile Bancorp »

FJ Capital Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

WSC

WillScot

$17.10

-0.05 (-0.29%)

17:10
09/21/18
09/21
17:10
09/21/18
17:10
Syndicate
Breaking Syndicate news story on WillScot »

WillScot files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DTEA

DAVIDsTEA

$2.50

-0.9 (-26.47%)

17:09
09/21/18
09/21
17:09
09/21/18
17:09
Hot Stocks
Breaking Hot Stocks news story on DAVIDsTEA »

TDM Asset Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NYT

New York Times

$23.45

0.3 (1.30%)

, EXPE

Expedia

$133.73

-0.77 (-0.57%)

17:08
09/21/18
09/21
17:08
09/21/18
17:08
Hot Stocks
Expedia president Bhutani joins New York Times board »

The New York Times…

NYT

New York Times

$23.45

0.3 (1.30%)

EXPE

Expedia

$133.73

-0.77 (-0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBTX

Independent Bank

$67.60

-1.15 (-1.67%)

, GBNK

Guaranty Bancorp

$30.20

-0.5 (-1.63%)

17:08
09/21/18
09/21
17:08
09/21/18
17:08
Conference/Events
Guaranty Bancorp to host special shareholder meeting »

Special Shareholder…

IBTX

Independent Bank

$67.60

-1.15 (-1.67%)

GBNK

Guaranty Bancorp

$30.20

-0.5 (-1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 25

    Sep

MPC

Marathon Petroleum

$83.37

1.44 (1.76%)

, ANDV

Andeavor

$154.80

2.19 (1.44%)

17:01
09/21/18
09/21
17:01
09/21/18
17:01
Conference/Events
Andeavor to host special shareholder meeting »

Special Shareholder…

MPC

Marathon Petroleum

$83.37

1.44 (1.76%)

ANDV

Andeavor

$154.80

2.19 (1.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 24

    Sep

ANDV

Andeavor

$154.80

2.19 (1.44%)

, MPC

Marathon Petroleum

$83.37

1.44 (1.76%)

16:59
09/21/18
09/21
16:59
09/21/18
16:59
Conference/Events
Marathon Petroleum to host special shareholder meeting »

Special Shareholder…

ANDV

Andeavor

$154.80

2.19 (1.44%)

MPC

Marathon Petroleum

$83.37

1.44 (1.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

EPRT

Essential Properties Realty Trust

$14.49

-0.015 (-0.10%)

16:45
09/21/18
09/21
16:45
09/21/18
16:45
Hot Stocks
Breaking Hot Stocks news story on Essential Properties Realty Trust »

Integrated Core…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBSI

Barrett Business

$63.67

0.04 (0.06%)

16:43
09/21/18
09/21
16:43
09/21/18
16:43
Hot Stocks
SEC says Barrett Business to pay $1.5M penalty over improper accounting »

The Securities and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SIGA

Siga Technologies

$7.25

0.5 (7.41%)

16:42
09/21/18
09/21
16:42
09/21/18
16:42
Conference/Events
Siga Technologies to host business news update conference call »

Management holds a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

SPY

SPDR S&P 500 ETF Trust

$292.03

-0.1774 (-0.06%)

, USO

United States Oil Fund

$14.95

0.145 (0.98%)

16:36
09/21/18
09/21
16:36
09/21/18
16:36
General news
Weekly CFTC Commitment of Traders highlights »

S&P500 net long 0.1K…

SPY

SPDR S&P 500 ETF Trust

$292.03

-0.1774 (-0.06%)

USO

United States Oil Fund

$14.95

0.145 (0.98%)

GLD

SPDR Gold Trust

$113.48

-0.77 (-0.67%)

FXE

Euro Currency Trust

$112.55

-0.27 (-0.24%)

FXC

CurrencyShares Canadian Dollar Trust

$76.37

-0.09 (-0.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.